Chai Discovery Revenue, Valuation, Funding & Investors

Chai Discovery is valued at $3.8B as of July 2026.

Last Chai Discovery valuation

$3.8B

Series C · Jul 2026

Last Chai Discovery funding round

$400M

Series C · Jul 2026

Chai Discovery revenue

$48M

Seed · Sep 2024

Key investors in Chai Discovery

  • Thrive Capital
  • OpenAI
  • Menlo Ventures
  • General Catalyst
  • SV Angel
  • Oak HC/FT

Chai Discovery Overview

About Chai Discovery

Chai Discovery is a San Francisco-based applied AI research lab, founded in 2024, that builds foundation models to predict and design interactions between biochemical molecules for drug discovery. Its models, including Chai-1, Chai-2, and Chai-3, are used to design molecules such as antibodies for difficult drug targets, with its most recent model achieving a de novo antibody hit rate far above prior computational methods. The company's technology has been used by pharmaceutical partners including Eli Lilly, Pfizer, and Novartis.


Founded

2024

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Licensing, Subscription

Revenue

$48M (Sep 2024)

Valuation

$3.8B (Jul 2026)

Chai Discovery Valuation

Chai Discovery is currently valued at $3.8B, based on its Series C in July 2026.

The $400M round was led by Index Ventures, with participation from General Catalyst, Yosemite, Menlo Ventures, Kleiner Perkins, Battery Ventures and 6 other investors.

Chai Discovery's valuation has grown 25x from $150M at its seed round in September 2024 to $3.8B in July 2026, across 4 priced rounds.

Chai Discovery valuation by funding round

Revenue multiple
Chai Discovery valuation by funding round
DateStageValuationRevenue Multiple
Jul 2026Series C$3.8B-
Dec 2025Series B$1.3B-
Aug 2025Series A$1.3B-
Sep 2024Seed$150M3.1x

Chai Discovery Revenue

Chai Discovery's latest recorded revenue is $48M, as of its seed round in September 2024. At a $150M valuation, that implies a 3.1x revenue multiple.

Chai Discovery revenue by funding round

Chai Discovery revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
Sep 2024$48M$150M3.1xSeed

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

Chai Discovery Funding History

Chai Discovery has raised a total of $630M across 5 funding rounds.

Chai Discovery's first fundraising round was a $30M seed round in September 2024. The most recent completed round was a $400M Series C in July 2026.

Chai Discovery funding rounds

Chai Discovery funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jul 2026Series CIndex Ventures (lead); General Catalyst; Yosemite; Menlo Ventures; Kleiner Perkins; Battery Ventures; OpenAI; Sequoia Capital; Oak HC/FT; UV Netware; Sapphire Ventures; Thrive Capital$400M$3.8BChai Discovery Inc. raised $400 million in Series C funding on July 14, 2026, at a post-money valuation of $3.8 billion, nearly tripling its previous $1.3 billion valuation from December 2025. The round was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital, and Dimension, with new investors including Battery Ventures, Bain Capital Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, and Avra Capital joining existing backers such as Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, and General Catalyst. The company issued convertible preferred shares and intends to use the funds to expand operations and accelerate R&D efforts in AI-driven molecular design. Chai Discovery, based in San Francisco, develops artificial intelligence models to predict biochemical molecule interactions and has discovered AI-designed antibodies that have reached major pharmaceutical companies, with its Chai-3 model achieving a 16% de novo antibody hit rate—100-fold better than prior computational methods. Total funding to date is approximately $630 million across four rounds since its 2024 founding, including $30M seed (2024), $70M Series A (August 2025), and $130M Series B (December 2025). Commercial pharma partners include Eli Lilly, Pfizer, and Novartis, demonstrating real-world AI deployment by leading drugmakers.
Dec 2025Series BGeneral Catalyst (lead); Oak HC/FT (lead); Yosemite; Emerson Collective; Menlo Ventures; SV Angel; Glade Brook Capital Partners; Neo; OpenAI; Thrive Capital; Lachy Groom; Dimension Capital$130M$1.3BChai Discovery is an applied AI research lab founded in 2024 that predicts and reprograms interactions between biochemical molecules to accelerate drug discovery, focusing on designing molecules with drug-like properties for challenging targets using foundation models like Chai-1 and the newly released Chai-2, which excels in de novo antibody design, GPCR agonists, and precise epitope binding validated by cryo-EM. The company raised $130 million in a Series B round on December 15, 2025, co-led by Oak HC/FT and General Catalyst, valuing it at $1.3 billion post-money and bringing total funding to over $225 million following a $70 million Series A in August 2025 led by Menlo Ventures. Participants included Thrive Capital, OpenAI, Dimension, Menlo Ventures, Lachy Groom, Yosemite, Neo, SV Angel, with new investors Emerson Collective and Glade Brook Capital Partners. Proceeds will accelerate R&D, expand commercialization, and develop a computer-aided design suite for molecules, aiming for IND-ready biologics in a single in silico pass while implementing a Responsible Deployment policy for selective access. Chai-2 demonstrates atomic-level accuracy and tackles undruggable targets, positioning the company to transform biology into an engineered discipline. Chai operates in the competitive AI drug discovery space, backed by OpenAI, with co-founder and CEO Josh Meier's prior experience at OpenAI and Facebook. The rapid follow-on from Series A highlights strong investor confidence amid 2025 breakthroughs in AI for therapeutics, with plans for 2026 deployment into pharma workflows.
Aug 2025Series AMenlo Ventures (lead); SV Angel; Fred Ehrsam; Neo; Anthology Fund; OpenAI; DCVC; Avenir; Thrive Capital; Lachy Groom; DST Global; Dimension Capital$70M$1.3BChai Discovery is an AI-powered biotech company founded in 2024 that develops foundation models to predict and reprogram biochemical molecule interactions, enabling the design of drugs for previously undruggable targets, including full-length monoclonal antibodies via its Chai-2 model. The company emerged from stealth earlier in 2025 with a $70M Series A led by Menlo Ventures in August, followed by a $130M Series B on December 15, 2025, co-led by Oak HC/FT and General Catalyst, valuing the company at $1.3 billion post-money and bringing total funding to over $225M. Participating investors included OpenAI, Thrive Capital, Menlo Ventures, Dimension, DST Global (implied via related funds), Lachy Groom, SV Angel, NEO/Yosemite, and newcomers Emerson Collective and Glade Brook. Chai Discovery's platform aims to transform drug discovery into a programmable engineering discipline, with Chai-2 demonstrating high success rates: 86% of designed antibodies had zero or one preclinical issues, and 24 of 28 targets yielded drug-like candidates. The Series B funds will accelerate research, product development, and commercialization of a 'computer-aided design suite' for molecules, positioning Chai to produce IND-ready biologics in silico while adhering to a Responsible Deployment policy limiting access. The rapid follow-on from Series A underscores strong investor confidence in AI-driven biotech, amid a sector hype shift toward proven utility. Board additions include Annie Lamont (Oak HC/FT) and Hemant Taneja (General Catalyst), with prior advisor Mikael Dolsten (ex-Pfizer CSO).
Jan 2025SeedFlat Capital--Flat Capital invested approximately SEK 3.3 million in Chai Discovery as the smallest of four holdings in its SEK 49 million portfolio of US AI companies. Chai Discovery develops AI models for predicting molecular structures and interactions to speed up drug development. The investment was made through a special purpose vehicle and, according to Flat's 2024 annual report, executed in the fourth quarter of 2024.
Sep 2024SeedOpenAI (lead); Thrive Capital (lead); Nitesh Banta$30M$150MChai Discovery is an AI-driven biotech startup founded in 2024 that develops foundation models like Chai 1 and Chai 2 to predict molecular interactions, enable de novo antibody design, and create a computer-aided design suite for engineering drug-like molecules targeting challenging diseases. The company raised $130 million in a Series B round at a $1.3 billion valuation, led by General Catalyst and Oak HC/FT, with participation from OpenAI, Thrive Capital, Menlo Ventures, Dimension, Neo, Yosemite Venture Fund, Lachy Groom, SV Angel, Glade Brook, and Emerson Collective. This brings total funding to over $225 million following a $70 million Series A led by Menlo Ventures in August 2024. The Series B funds will accelerate research, product development, and commercialization efforts. Annie Lamont of Oak HC/FT and Hemant Taneja of General Catalyst joined the board. CEO Josh Meier, formerly at OpenAI and Facebook, leads the effort to revolutionize drug discovery by improving success rates in custom antibody design over traditional methods. Chai operates in a competitive AI-biotech landscape with players like Google DeepMind's AlphaFold, amid surging VC interest in AI for faster drug development. A prior seed round of nearly $30 million led by Thrive Capital valued the company at $150 million, but the queried round matches the later Series B with OpenAI and Thrive Capital participation, though announced later than the approximate September 2024 date.

Who has invested in Chai Discovery?

25 investors have backed Chai Discovery across its funding rounds, including Thrive Capital, OpenAI, Menlo Ventures, General Catalyst, SV Angel and Oak HC/FT.

Lead investors include Index Ventures, General Catalyst, Oak HC/FT, Menlo Ventures, OpenAI and 1 other investor.


Chai Discovery Investors

Investors in Chai Discovery by funding rounds participated
InvestorHQRoundsRoleFirst check
OpenAIUnited StatesSan Francisco, CA4LeadSep 2024
Thrive CapitalUnited StatesNew York City, NY4LeadSep 2024
Menlo VenturesUnited StatesSan Francisco, CA3LeadAug 2025
General CatalystUnited StatesSan Francisco, CA2LeadDec 2025
YosemiteUnited StatesUnited States2ParticipantDec 2025
SV AngelUnited StatesSan Francisco, CA2ParticipantAug 2025
NeoUnited StatesSan Francisco, CA2ParticipantAug 2025
Oak HC/FTUnited StatesGreenwich, CT2LeadDec 2025
Lachy GroomUnited StatesSan Francisco, CA2ParticipantAug 2025
Dimension CapitalUnited StatesNew York City, NY2ParticipantAug 2025
Emerson CollectiveUnited StatesSan Francisco, CA1ParticipantDec 2025
Index VenturesUnited KingdomLondon1LeadJul 2026
Kleiner PerkinsUnited StatesSan Francisco, CA1ParticipantJul 2026

This data is available for Pro users. Sign up to see all 25 Chai Discovery investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Chai Discovery Competitors

Chai Discovery competitors include listed companies like Arcs Co and Infleqtion, and private ones like Astromech, Sword Health, Synthesia and Relativity Space.

Public and private companies comparable to Chai Discovery
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
AstromechUnited StatesUnited StatesPrivate--$3.8B-
Arcs CoJapanJapanPublicly listed$4B$185M$1.3B0.2x
Sword HealthUnited StatesNew York City, NYPrivate$240M-$4B16.7x
SynthesiaUnited KingdomLondonPrivate$100M-$4B40.0x
Relativity SpaceUnited StatesLos Angeles, CAPrivate--$4.2B-
InfleqtionUnited StatesUnited StatesPublicly listed$29M($52M)$3.1B64.5x

Chai Discovery Public Comps

Chai Discovery is still privately-owned, but its public comps include XtalPi, Tenable, CorVel, Fermi, Infleqtion, Shenzhen Intellifusion, Adaptive Biotech, SoundHound, Intsig Information and Bloomage BioTechnology.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
XtalPi$120M$22M24.8x21.5x134.0x(141.6x)
Tenable$999M$31M4.1x3.9x129.9x15.3x
CorVel$959M$175M3.5x-19.1x-
Fermi-($490M)-281.8x(7.5x)(63.2x)
Infleqtion$29M($52M)92.3x64.5x(50.9x)(60.0x)
Shenzhen Intellifusion$200M($3M)14.3x14.6x(952.5x)(1086.5x)
Adaptive Biotech$277M($39M)16.7x16.0x(117.9x)675.9x
SoundHound$169M$19M14.6x11.3x132.5x(35.5x)

This data is available for Pro users. Sign up to see all Chai Discovery competitors and their valuation data.

Start Free Trial

Common questions about Chai Discovery

When was Chai Discovery founded?Chai Discovery was founded in 2024.
Where is Chai Discovery headquartered?Chai Discovery is headquartered in San Francisco, CA, United States.
Is Chai Discovery publicly listed?No, Chai Discovery is a private, VC-backed company.
What is Chai Discovery's valuation?Chai Discovery was last valued at $3.8B in its Series C in July 2026.
How much funding has Chai Discovery raised?Chai Discovery has raised $630M across 5 funding rounds.
What was Chai Discovery's last funding round?Chai Discovery's last funding round was a $400M Series C in July 2026, led by Index Ventures.
Who are Chai Discovery's investors?Chai Discovery's investors include OpenAI, Thrive Capital, Menlo Ventures, General Catalyst, Yosemite, SV Angel, Neo, Oak HC/FT, Lachy Groom, Dimension Capital and 15 others.
What is Chai Discovery's revenue?Chai Discovery's latest recorded revenue is $48M (September 2024).
What is Chai Discovery's revenue multiple?Chai Discovery's latest valuation implies a 3.1x revenue multiple ($150M valuation on $48M of revenue).
Which companies are comparable to Chai Discovery?Companies comparable to Chai Discovery include Astromech, Arcs Co, Sword Health, Synthesia, Relativity Space and Infleqtion.

See companies similar to Chai Discovery

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial